| Literature DB >> 35401392 |
Fettah Eren1, Cihat Ozguncu1, Serefnur Ozturk1.
Abstract
Introduction and Aim: Stroke is a disease with high mortality and morbidity. Although studies are generally performed on all patients with stroke, it is known that gender has an effect on etiology and prognosis. This study aimed to determine the importance of clinical stroke scales and laboratory markers in determining the short-term prognosis of female patients with ischemic stroke of anterior circulation. Materials andEntities:
Keywords: female; gender; prognosis; short term; stroke; women
Year: 2022 PMID: 35401392 PMCID: PMC8988246 DOI: 10.3389/fneur.2022.812647
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Chronic diseases, presenting symptoms, and affected cerebral localizations in all patients with ischemic stroke.
|
|
|
| |
|---|---|---|---|
| Age (year), mean ± SD | 69.53 ± 14.51 | 64.27 ± 13.29 | 0.001*a |
| Scores, mean ± SD | |||
| NIH stroke scale | 8.20 ± 7.20 | 6.30 ± 5.35 | 0.001*a |
| Glasgow coma Scale | 13.67 ± 2.48 | 14.08 ± 2.02 | 0.001*a |
| SEDAN score | 2.05 ± 1.23 | 1.56 ± 1.15 | 0.001*a |
| THRIVE score | 3.20 ± 1.87 | 2.27 ± 1.59 | 0.001*a |
| Modified Rankin Scale | 3.04 ± 1.69 | 2.55 ± 1.68 | 0.001*a |
| Chronic diseases, | |||
| Diabetes mellitus | 297 (40.5) | 244 (28.4) | 0.001*b |
| Hypertension | 502 (68.5) | 460 (53.6) | 0.001*b |
| Coronary artery disease | 188 (25.2) | 258 (30.1) | 0.057b |
| Malignancy | 46 (6.3) | 61 (7.1) | 0.547b |
| Chronic renal failure | 31 (4.2) | 39 (4.5) | 0.807b |
| Dementia | 44 (6.0) | 15 (1.7) | 0.001*b |
| Hyperlipidemia | 64 (10.5) | 45 (6.6) | 0.048*b |
| Atrial fibrillation | 208 (28.4) | 119 (13.9) | 0.001*b |
| Smoking, | |||
| Yes | 7 (0.9) | 75 (8.7) | 0.001*b |
| No | 736 (99.1) | 783 (91.3) | |
| Initial symptoms, | |||
| Consciousness | |||
| Alert | 499 (68.1) | 659 (76.8) | 0.001*b |
| Other (confused, somnolence, stupor, or coma) | 234 (31.9) | 199 (23.2) | |
| Speech | |||
| Normal | 370 (43.1) | 268 (36.6) | 0.216b |
| Aphasia or dysarthria | 363 (56.9) | 590 (63.4) | |
| Cranial nerve involvement | |||
| Yes | 245 (33.4) | 276 (32.2) | 0.630b |
| No | 488 (66.6) | 582 (67.8) | |
| Motor deficiency | |||
| Yes | 587 (81.1) | 714 (83.2) | 0.512b |
| No | 146 (19.9) | 144 (16.8) | |
| Site of vessel occlusion | |||
| Right | 438 (59.8) | 502 (58.6) | 0.356b |
| Left | 295 (40.2) | 356 (41.4) | |
| Treatment | |||
| IV thrombolysis | 47 (6.4) | 77 (9.0) | 0.229b |
| Endovascular thrombectomy | 36 (4.9) | 49 (5.7) | 0.224b |
| IV thrombolysis and thrombectomy | 44 (6.0) | 49 (5.7) | 0.504b |
*Statistically significant value. SD, Standard deviation; IV, Intravenous.
.
.
Evaluation of prognostic status according to gender.
|
|
|
| |
|---|---|---|---|
| Length of hospitalization | |||
| Mean ± SD (Minimum–maximum) | 12.63 ± 10.95 (1–87) | 11.81 ± 12.55 (1–155) | 0.003*a |
| Need for intensive care | |||
| Yes | 342 (46.7%) | 336 (39.2%) | 0.003*b |
| No | 391 (53.3%) | 522 (60.8%) | |
| Need for mechanical ventilation | |||
| Yes | 147 (20.1%) | 123 (14.3%) | 0.002*b |
| No | 586 (79.9%) | 735 (85.7%) | |
| Complication of central system | |||
| Yes | 71 (%9.7%) | 87 (10.1%) | 0.801b |
| No | 662 (90.3%) | 771 (89.9%) | |
| Decompressive surgery | |||
| Yes | 26 (3.5%) | 37 (4.3%) | 0.519b |
| No | 707 (96.5%) | 821 (95.7%) | |
| Exitus | |||
| Yes | 134 (18.3%) | 103 (12.0%) | 0.001*b |
| No | 599 (81.7%) | 755 (88.0%) | |
| Discharge disability | |||
| Dependent | 243 (40.7%) | 199 (26.4%) | 0.001*b |
| Independent | 354 (59.3%) | 556 (73.6%) | |
SD, Standard deviation.
*Statistically significant value.
.
.
Data are expressed as numbers (percentage) unless otherwise indicated.
Stroke scores and laboratory parameters according to mortality status in female patients with ischemic stroke.
|
|
|
| |
|---|---|---|---|
| NIHSS | 17.21 ± 7.09 (1–35) | 6.19 ± 5.48 (0–25) | 0.001*a |
| GCS | 10.29 ± 3.45 (3–15) | 14.42 ± 1.33 (7–15) | 0.001*a |
| SEDAN score | 2.91 ± 1.16 (0–6) | 1.84 ± 1.15 (0–6) | 0.001*a |
| THRIVE score | 5.07 ± 1.64 (0–9) | 2.79 ± 1.65 (0–8) | 0.001*a |
| mRS | 4.60 ± 0.83 (1–5) | 2.69 ± 1.63 (0–5) | 0.001*a |
| Blood glucose (mg/dL) | 169.71 ± 88.54 (75–718) | 152.61 ± 74.67 (71–558) | 0.009*a |
| Creatinine (mg/dL) | 1.06 ± 0.56 (0.39–3.69) | 0.88 ± 0.57 (0.34–6.26) | 0.001*a |
| Hemoglobin (g/dL) | 12.26 ± 1.68 (8.20–16.90) | 12.65 ± 1.72 (4.6–21.9) | 0.020*a |
| Leukocyte (K/uL) | 11.14 ± 5.23 (2.50–40.10) | 9.00 ± 5.08 (1.4–107.8) | 0.001*a |
| Urea (K/uL) | 58.94 ± 28.04 (16–165) | 44.11 ± 23.34 (11–228) | 0.001*a |
| Albumin (g/dL) | 2.94 ± 0.61 (1.5–4.30) | 3.40 ± 0.50 (1.8–4.4) | 0.001*a |
| C-reactive protein (mg/dL) | 92.58 ± 98.71 (2.2–470.0) | 41.38 ± 66.58 (0.3–476) | 0.001*a |
| LDL-cholesterol (mg/dL) | 114.80 ± 33.13 (59–191) | 126.25 ± 41.09 (37–301) | 0.150a |
| HDL-cholesterol (mg/dL) | 44.92 ± 16.59 (20–91) | 42.68 ± 10.58 (17–96) | 0.643a |
| Triglyceride (mg/dL) | 143.50 ± 58.01 (49–330) | 160.59 ± 93.67 (40–627) | 0.052a |
| Treatment ( | |||
| IV thrombolysis | 15 (11.2) | 32 (5.3) | 0.841b |
| Endovascular thrombectomy | 11 (8.2) | 25 (4.2) | |
| IV thrombolysis and thrombectomy | 16 (11.9) | 28 (4.7) | |
NIHSS, NIH stroke score; GCS, Glasgow coma score; mRS, Modified Rankin score; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; n, Number; IV, Intravenous.
*Statistical significance value.
.
.
Data are shown as mean ± SD (minimum–maximum) unless otherwise indicated.
Stroke scores and laboratory findings according to short-term disability status in female patients with ischemic stroke.
|
|
|
| |
|---|---|---|---|
| NIHSS | 3.01 ± 2.96 (0–22) | 10.77 ± 5.05 (2–25) | 0.001*a |
| GCS | 14.90 ± 0.41 (8–15) | 11.72 ± 1.82 (5–15) | 0.001*a |
| SEDAN score | 1.50 ± 1.10 (0–6) | 2.26 ± 1.08 (0–5) | 0.001*a |
| THRIVE score | 2.22 ± 1.32 (0–5) | 3.60 ± 1.75 (0–8) | 0.001* |
| mRS | 1.62± 1.15 (0–5) | 4.24 ± 0.74 (3–5) | 0.001*a |
| Blood Glucose (mg/dL) | 149.86 ± 76.26 (73–558) | 156.85 ± 74.04 (71–534) | 0.016* |
| Creatinine (mg/dL) | 0.89 ± 0.60 (0.37–6.26) | 0.88 ± 0.56 (0.34–5.55) | 0.828a |
| Hemoglobin (g/dL) | 12.66 ± 1.61 (4.6–16.3) | 12.66 ± 1.88 (7.50–21.9) | 0.793a |
| Leukocyte (K/uL) | 8.71 ± 5.95 (1.4–107.8) | 9.44 ± 3.43 (3.4–26.8) | 0.001*a |
| Urea (K/uL) | 41.84 ± 21.42 (13–221) | 47.46 ± 25.64 (11–228) | 0.001*a |
| Albumin (g/dL) | 3.57 ± 0.39 (2.3–4.3) | 3.30 ± 0.53 (1.8–4.4) | 0.001*a |
| C-reactive protein (mg/dL) | 31.61 ± 58.72 (0.3–476) | 48.99 ± 71.40 (1.11–471) | 0.002*a |
| LDL-cholesterol (mg/dL) | 124.75 ± 42.90 (49–301) | 129.30 ± 37.64 (37–249) | 0.080 |
| HDL-cholesterol (mg/dL) | 43.17 ± 10.11 (24–96) | 41.94 ± 11.33 (17–73) | 0.196a |
| Triglyceride (mg/dL) | 167.35 ± 98.08 (48–627) | 158.14 ± 84.42 (49–459) | 0.082a |
| Treatment ( | |||
| IV thrombolysis | 16 (4.5) | 15 (6.2) | 0.016*b |
| Endovascular thrombectomy | 4 (1.1) | 21 (8.6) | |
| IV thrombolysis and thrombectomy | 8 (2.3) | 20 (8.2) |
NIHSS, NIH stroke score; GCS, Glasgow coma score; mRS, Modified Rankin score; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; n, Number; IV, Intravenous.
*Statistical significance value.
.
.
Data are shown as mean ± SD (minimum–maximum unless otherwise indicated).
Prediction of the mortality status and dependency at the discharge with initial disability scores.
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
| ||||
| Prediction for mortality | |||||
| GCS*a | 0.611 | 0.070 | 0.534 | 0.701 | 0.001 |
| SEDAN*a | 1.307 | 0.125 | 1.024 | 1.669 | 0.031 |
| mRS*a | 1.424 | 0.139 | 1.085 | 1.870 | 0.011 |
| Prediction for dependency | |||||
| NIHSS**a | 1.611 | 0.045 | 1.474 | 1.762 | 0.001 |
| NIHSS***b | 1.726 | 0.035 | 1.612 | 1.847 | 0.001 |
GCS, Glasgow coma score; mRS, Modified Rankin score; NIHSS, NIH stroke score.
.
**Model established with the NIHSS, the GCS, SEDAN, and THRIVE scores to predict dependency (independent or dependent).
***Model established with the NIHSS, the GCS, SEDAN, and THRIVE scores to predict dependency (mRS: 0–5).
.
.